AIDS vaccines and preexposure prophylaxis: Is synergy possible?

AIDS Research and Human Retroviruses

Volumn 27, Issue 6, 2011, Pages 669-680

  Excler, Jean Louis ^a   Rida, Wasima ^b   Priddy, Frances ^a   Gilmour, Jill ^c   McDermott, Adrian B ^a   Kamali, Anatoli ^d   Anzala, Omu ^e   Mutua, Gaudensia ^e   Sanders, Eduard J ^f,g   Koff, Wayne ^a   Berkley, Seth ^a   Fast, Patricia ^a  

^a INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^b Biostatistics Consultant   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^e UNIVERSITY OF NAIROBI   (Kenya)

^f KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^g UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO;

ADAPTIVE IMMUNITY; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; VACCINATION; VIRUS LOAD;

AIDS VACCINES; ANIMALS; ANTI-HIV AGENTS; DRUG SYNERGISM; HIV INFECTIONS; HUMANS; RISK ASSESSMENT; VIRAL LOAD;

EID: 79957604683     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2010.0206     Document Type: Article

References (109)

1. UNAIDS: AIDS Epidemic Update. December 2009
2. McCoy SI, Kangwende RA, and Padian NS: Behavior change interventions to prevent HIV infection among women living in low and middle income countries: A systematic review. AIDS Behav 2010;14:469-482
3. Padian NS, McCoy SI, Balkus JE, et al.: Weighing the gold in the gold standard: Challenges in HIV prevention research. AIDS 2010;24:621-635
4. Walker BD and Burton DR: Toward an AIDS vaccine. Science 2008;320:760-764 (Pubitemid 351929619)
5. Buchbinder SP, Mehrotra DV, Duerr A, et al.: Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372:1881-1893
6. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al.: Vaccination with ALVAC and AIDSVAX to prevent HIV- 1 infection in Thailand. N Engl J Med 2009;361:2209-2220
7. Koff WC: Accelerating HIV vaccine development. Nature 2010;464:161-162
8. Barouch DH: Challenges in the development of an HIV-1 vaccine. Nature 2008;455:613-619
9. Gupta SB, Jacobson LP, Margolick JB, et al.: Estimating the benefit of an HIV-1 vaccine that reduces viral load set point. J Infect Dis 007;195:546-550 (Pubitemid 46214397)
10. Cardo DM, Culver DH, Ciesielski CA, et al.: A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 1997;337:1485-1490 (Pubitemid 27495773)
11. Roland ME: Postexposure prophylaxis after sexual exposure to HIV. Curr Opin Infect Dis 2007;20:39-46 (Pubitemid 46052125)
12. Poynten, IM, Smith DE, Cooper DA, et al.: The public health impact of widespread availability of nonoccupational postexposure prophylaxis against HIV. HIV Med 2007;8: 374-381 (Pubitemid 47163269)
13. Suksomboon N, Poolsup N, and Ket-Aim S: Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection. J Clin Pharm Ther 2007;32:293-311 (Pubitemid 46699523)
14. McIntyre J: Use of antiretrovirals during pregnancy and breastfeeding in low-income and middle-income countries. Curr Opin HIV AIDS 2010;5:48-53
15. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al.: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329:1168-1174
16. Igarashi T, Endo Y, Nishimura Y, et al.: Early control of highly pathogenic simian immunodeficiency virus/human immunodeficiency virus chimeric virus infections in rhesus monkeys usually results in long-lasting asymptomatic clinical outcomes. J Virol 2003;77:10829-10840 (Pubitemid 37204276)
17. Tsai CC, Emau P, Follis KE, et al.: Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl)adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998;72:4265-4273 (Pubitemid 28188732)
18. Tsai CC, Follis KE, Sabo A, et al.: Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine. Science 1995;270:1197-1199
19. Van Rompay KK, McChesney MB, Aguirre NL, et al.: Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. J Infect Dis 2001;184:429-438 (Pubitemid 32718506)
20. Garcia-Lerma JG, Otten RA, Qari SH, et al.: Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 2008;5:e28
21. Subbarao S, Otten RA, Ramos A, et al.: Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis 2006;194:904-911 (Pubitemid 44454075)
22. Kubo M, Nishimura Y, Shingai M, et al.: Initiation of antiretroviral therapy 48 hours after infection with simian immunodeficiency virus potently suppresses acute-phase viremia and blocks the massive loss of memory CD4+ T cells but fails to prevent disease. J Virol 2009;83:7099-7108
23. Van Rompay KK, Cherrington JM, Marthas ML, et al.: 9-[2- (Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA. Antimicrob Agents Chemother 1999;43:802-812 (Pubitemid 29165743)
24. Schooley RT, Ruane P, Myers RA, et al.: Tenofovir DF in antiretroviral-experienced patients: Results from a 48- week, randomized, double-blind study. AIDS 2002;16: 1257-1263 (Pubitemid 34666660)
25. Barditch-Crovo P, Deeks SG, Collier A, et al.: Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001;45:2733-2739 (Pubitemid 32906664)
26. Pruvost A, Negredo E, Benech H, et al.: Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2005;49:1907-1914 (Pubitemid 40631606)
27. Wang LH, Begley J, St Claire RL, 3rd, et al.: Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. AIDS Res Hum Retroviruses 2004;20:1173-1182 (Pubitemid 39557868)
28. Hawkins T, Veikley W, St Claire RL, 3rd, et al.: Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr 2005;39:406-411 (Pubitemid 41003784)
29. Weber J, Chakraborty B, Weberova J, et al.: Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation. J Clin Microbiol 2005;43:1395-1400 (Pubitemid 40364970)
30. Robbins BL, Srinivas RV, Kim C, et al.: Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9- R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl) PMPA. Antimicrob Agents Chemother 1998;42:612-617 (Pubitemid 28114817)
31. Vourvahis M, Tappouni HL, Patterson KB, et al.: The pharmacokinetics and viral activity of tenofovir in the male genital tract. J Acquir Immune Defic Syndr 2008;47:329-333 (Pubitemid 351619418)
32. Cohen MS, Gay C, Kashuba AD, et al.: Narrative review: Antiretroviral therapy to prevent the sexual transmission of HIV-1 Ann Intern Med 2007;146:591-601 (Pubitemid 351650540)
33. Garcia-Lerma, JG, Paxton L, Kilmarx PH, et al.: Oral preexposure prophylaxis for HIV prevention. Trends Pharmacol Sci 2010;31:74-81
34. De Cock KM, Gilks CF, Lo YR, et al.: Can antiretroviral therapy eliminate HIV transmission? Lancet 2009;373:7-9
35. Royce RA, Sena A, Cates W Jr, et al.: Sexual transmission of HIV. N Engl J Med 1997;336:1072-1078 (Pubitemid 27163861)
36. Attia S, Egger M, Muller M, et al.: Sexual transmission of HIV according to viral load and antiretroviral therapy: Systematic review and meta-analysis. AIDS 2009;23:1397-1404
37. Chakraborty H, Sen PK, Helms RW, et al.: Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: A probabilistic empiric model. AIDS 2001;15:621-627 (Pubitemid 32281358)
38. Fideli US, Allen SA, Musonda R, et al.: Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses 2001;17:901-910 (Pubitemid 32881333)
39. Quinn TC, Wawer MJ, Sewankambo N, et al.: Viral load and heterosexual transmission of human immunodeficiency virus type 1 Rakai Project Study Group. N Engl J Med 2000;342:921-929 (Pubitemid 30177052)
40. Tovanabutra S, Robison V, Wongtrakul J, et al.: Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr 2002;29:275-283 (Pubitemid 34208536)
41. Wawer MJ, Gray RH, Sewankambo NK, et al.: Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005;191:1403-1409 (Pubitemid 40563350)
42. Coombs RW, Reichelderfer PS, and Landay AL: Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS 2003;17:455-480 (Pubitemid 36293099)
43. Pilcher CD, Joaki G, Hoffman IF, et al.: Amplified transmission of HIV-1: Comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS 2007;21:1723-1730 (Pubitemid 47237559)
44. Sheth PM, Kovacs C, Kemal KS, et al.: Persistent HIV RNA shedding in semen despite effective antiretroviral therapy. AIDS 2009;23:2050-2054
45. Shen C, Ding M, Craigo JK, et al.: Genetic characterization of HIV-1 from semen and blood from clade C-infected subjects from India and effect of therapy in these body compartments. Virology 2010;401:190-196
46. Pasquier C, Saune K, Raymond S, et al.: Determining seminal plasma human immunodeficiency virus type 1 load in the context of efficient highly active antiretroviral therapy. J Clin Microbiol 2009;47:2883-2887
47. Montaner JS, Hogg R, Wood E, et al.: The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006;368:531-536 (Pubitemid 44142776)
48. Lima VD, Johnston K, Hogg RS, et al.: Expanded access to highly active antiretroviral therapy: A potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis 2008;198:59-67 (Pubitemid 351920290)
49. Dieffenbach CW and Fauci AS: Universal voluntary testing and treatment for prevention of HIV transmission. JAMA 2009;301:2380-2382
50. Granich RM, Gilks CF, Dye C, et al.: Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: A mathematical model. Lancet 2009;373:48-57
51. Granich R, Crowley S, Vitoria M, et al.: Highly active antiretroviral treatment for the prevention of HIV transmission. J Int AIDS Soc 2010;13:1
52. Sullivan P, Kayitenkore K, Chomba E, et al.: Reduction of HIV transmission risk and high risk sex while prescribed ART: Results from discordant couples in Rwanda and Zambia. In: 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, 2009 Abstract 52bLB.
53. Wagner B and Blower S: Costs of eliminating HIV in South Africa have been underestimated. Lancet 2010;376:953-954
54. Allen S, Chomba E, and Karita E: Cost-per-HIV infection averted in Africa by couples' HIV testing vs. antiretroviral treatment: HIV prevention in a 2010 global economy. AIDS Res Human Retroviruses 2010;26:A-20 Abstract OA0706
55. Abdool Karim SS: Antiretroviral prophylaxis for the prevention of HIV infection: Future implementation challenges. HIV Therapy 2009;3:3-6
56. Wilson NA, Reed J, Napoe GS, et al.: Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239 J Virol 2006;80:5875-5885 (Pubitemid 43849165)
57. Watkins DI, Burton DR, Kallas EG, et al.: Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 2008;14:617-621 (Pubitemid 351809543)
58. McDermott AB, Mitchen J, Piaskowski S, et al.: Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: A model for the evaluation of vaccine efficacy in nonhuman primates. J Virol 2004;78:3140-3144 (Pubitemid 38314372)
59. Polyanskaya N, Bergmeier LA, Sharpe SA, et al.: Mucosal exposure to subinfectious doses of SIV primes gut-associated antibody-secreting cells and T cells: Lack of enhancement by nonneutralizing antibody. Virology 2001;279:527-538 (Pubitemid 34161116)
60. Haase AT: Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010;464:217-223
61. Keele BF, Li H, Learn GH, et al.: Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1 J Exp Med 2009;206:1117-1134
62. Stone M, Keele BF, Ma ZM, et al.: A limited number of simian immunodeficiency virus (SIV) env variants are transmitted to rhesus macaques vaginally inoculated with SIVmac251 J Virol 2010;84:7083-7095
63. Zhou Q, Hidajat R, Peng B, et al.: Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251). Vaccine 2007;25:8021-8035 (Pubitemid 47632993)
64. Schulte R, Suh YS, Sauermann U, et al.: Mucosal prior to systemic application of recombinant adenovirus boosting is more immunogenic than systemic application twice but confers similar protection against SIV-challenge in DNA vaccine-primed macaques. Virology 2009;383:300-309
65. Barnett SW, Srivastava IK, Kan E, et al.: Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 2008;22:339-348
66. Miyazawa M, Lopalco L, Mazzotta F, et al.: The 'immunologic advantage' of HIV-exposed seronegative individuals. AIDS 2009;23:161-175
67. Alter G, Teigen N, Ahern R, et al.: Evolution of innate and adaptive effector cell functions during acute HIV-1 infection. J Infect Dis 2007;195:1452-1460 (Pubitemid 46717463)
68. Horton RE, McLaren PJ, Fowke K, et al.: Cohorts for the study of HIV-1-exposed but uninfected individuals: Benefits and limitations. J Infect Dis 2010;202(Suppl 3): S377-381
69. Rowland-Jones SL, Dong T, Fowke KR, et al.: Cytotoxic T cell responses to multiple conserved HIV epitopes in HIVresistant prostitutes in Nairobi. J Clin Invest 1998;102:1758-1765 (Pubitemid 28516261)
70. Kaul R, Plummer FA, Kimani J, et al.: HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV- 1-resistant prostitutes in Nairobi. J Immunol 2000;164:1602-1611 (Pubitemid 30067280)
71. Kaul R, MacDonald KS, Nagelkerke NJ, et al.: HIV viral set point and host immune control in individuals with HIVspecific CD8+ T-cell responses prior to HIV acquisition. AIDS 2010;24:1449-1454
72. Legrand FA, Nixon DF, Loo CP, et al.: Strong HIV-1-specific T cell responses in HIV-1-exposed uninfected infants and neonates revealed after regulatory T cell removal. PLoS One 2006;1:e102
73. Restrepo C, Rallon NI, Del Romero J, et al.: low-level exposure to HIV induces virus-specific T cell responses and immune activation in exposed HIV-seronegative individuals. J Immunol 2010;185:982-989
74. Cranage M, Sharpe S, Herrera C, et al.: Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med 2008;5:e157; discussion e157
75. Wodarz D, Arnaout RA, Nowak MA, et al.: Transient antiretroviral treatment during acute simian immunodeficiency virus infection facilitates long-term control of the virus. Philos Trans R Soc Lond B Biol Sci 2000;355:1021-1029
76. Tsai CC, Emau P, Sun JC, et al.: Post-exposure chemoprophylaxis (PECP) against SIV infection of macaques as a model for protection from HIV infection. J Med Primatol 2000;29:248-258
77. Spring M, Stahl-Hennig C, Stolte N, et al.: Enhanced cellular immune response and reduced CD8(ρ) lymphocyte apoptosis in acutely SIV-infected Rhesus macaques after shortterm antiretroviral treatment. Virology 2001;279:221-232 (Pubitemid 34161013)
78. Van Rompay KK, Singh RP, Brignolo LL, et al.: The clinical benefits of tenofovir for simian immunodeficiency virusinfected macaques are larger than predicted by its effects on standard viral and immunologic parameters. J Acquir Immune Defic Syndr 2004;36:900-914 (Pubitemid 38944085)
79. Van Rompay KK, Singh RP, Pahar B, et al.: CD8+-cellmediated suppression of virulent simian immunodeficiency virus during tenofovir treatment. J Virol 2004;78: 5324-5337 (Pubitemid 38581483)
80. Kumar A, Buch S, Foresman L, et al.: Development of virusspecific immune responses in SHIV(KU)-infected macaques treated with PMPA. Virology 2001;279:97-108 (Pubitemid 34161003)
81. Van Rompay KK, Dailey PJ, Tarara RP, et al.: Early shortterm 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn Rhesus macaques. J Virol 1999;73:2947-2955 (Pubitemid 29135683)
82. Kersh E, Adams D, and Youngpairoj A: Mucosal SHIV exposures and oral PrEP can induce specific T cell responses, and can have a chemo-vaccination effect. AIDS Res Human Retroviruses 201026:A-18 Abstract OA0702
83. Lifson JD, Rossio JL, Piatak M Jr, et al.: Role of CD8(ρ) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J Virol 2001;75:10187-10199 (Pubitemid 32948049)
84. Rosenwirth B, ten Haaft P, Bogers WM, et al.: Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques. J Virol 2000;74:1704-1711 (Pubitemid 30434026)
85. Van Rompay, KK, Marthas ML, Lifson JD, et al.: Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques. AIDS Res Hum Retroviruses 1998;14:761-773 (Pubitemid 28265737)
86. Lifson JD, Rossio JL, Arnaout R, et al.: Containment of simian immunodeficiency virus infection: Cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment. J Virol 2000; 74:2584-2593 (Pubitemid 30117567)
87. Garcia-Lerma G, Cong ME, Mitchell J, et al.: Prevention of rectal simian HIV transmission in macaques by intermittent preexposure prophylaxis with oral Truvada. In: 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, 2009 Abstract 47
88. Lifson JD, Piatak M Jr, Cline AN, et al.: Transient early postinoculation anti-retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut-associated lymphoid tissues in SIVmac239-infected rhesus macaques, but not resistance to rechallenge. J Med Primatol 2003; 32:201-210 (Pubitemid 37021245)
89. Mori K, Yasutomi Y, Sawada S, et al.: Suppression of acute viremia by short-term postexposure prophylaxis of simian/ human immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW420867) allows for development of potent antiviral immune responses resulting in efficient containment of infection. J Virol 2000;74:5747-5753 (Pubitemid 30412940)
90. Kersh EN, Luo W, Adams DR, et al.: No evidence of occult SHIV infection as demonstrated by CD8+ cell depletion after chemoprophylaxis-induced protection from mucosal infection in rhesus macaques. AIDS Res Hum Retroviruses 2008;24:543-546 (Pubitemid 351571040)
91. Kersh EN, Luo W, Adams DR, et al.: Repeated rectal SHIVSF162P3 exposures do not consistently induce sustained T cell responses prior to systemic infection in the repeat-low dose preclinical macaque model. AIDS Res Hum Retroviruses 2009;25:905-917
92. Prada N, Davis B, Jean-Pierre P, et al.: Drug-susceptible HIV-1 infection despite intermittent fixed-dose combination tenofovir/emtricitabine as prophylaxis is associated with low-level viremia, delayed seroconversion, and an attenuated clinical course. J Acquir Immune Defic Syndr 2008;49:117-122
93. Moore JP: Can vaccines and microbicides be co-developed. In: AIDS Vaccine, Cape Town, South Africa, 2008 Abstract RT01-01
94. Shattock R: Vaccines and microbicides? Getting the best out of new prevention technology. In: AIDS Vaccine, Cape Town, South Africa, 2008 Abstract RT01-04
95. Mehrotra DV, Li X, and Gilbert PB: A comparison of eight methods for the dual-endpoint evaluation of efficacy in a proofof- concept HIV vaccine trial. Biometrics 2006;62:893-900
96. Weinberg CR: Less is more, except when less is less: Studying joint effects. Genomics 2009;93:10-12
97. Rida WN and Lawrence DN: Some statistical issues in HIV vaccine trials. Stat Med 1994;13:2155-2177 (Pubitemid 24330397)
98. Stampfer MJ, Buring JE, Willett W, et al.: The 2 x 2 factorial design: Its application to a randomized trial of aspirin and carotene in U.S. physicians. Stat Med 1985;4:111-116 (Pubitemid 15055340)
99. Fontana RJ: Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009;49:S185-195
100. Fux, CA, Rauch A, Simcock M, et al.: Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. Antivir Ther 2008;13:1077-1082
101. Excler JL, Rida W, Priddy F, et al.: A strategy for accelerating the development of preventive AIDS vaccines. AIDS 2007;21:2259-2263 (Pubitemid 350287451)
102. Gilbert PB: Some design issues in phase 2B vs phase 3 prevention trials for testing efficacy of products or concepts. Stat Med 2010;29:1061-1071
103. Karita E, Ketter N, Price MA, et al.: CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa. PLoS One 2009;4:e4401
104. Eller LA, Eller MA, Ouma B, et al.: Reference intervals in healthy adult Ugandan blood donors and their impact on conducting international vacci e trials. PLoS One 2008; 3:e3919
105. Vissers DC, Voeten HA, Nagelkerke NJ, et al.: The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: A simulation study. PLoS One 2008; 3:e2077
106. Montaner J: Treatment as Prevention: HAART Expansion- A Powerful Strategy to Reduce AIDS Morbidity and Mortality and HIV Incidence. WHO, Geneva, 2010
107. Gray RH, Li X, Wawer MJ, et al.: Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda. AIDS 2003;17:1941-1951 (Pubitemid 37070280)
108. Haase AT: Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 2005;5:783-792 (Pubitemid 41400852)
109. Miller CJ, Li Q, Abel K, et al.: Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol 2005;79:9217-9227 (Pubitemid 40934833)